In February, the White House’s Council of Economic Advisers (CEA) released a 30-page white paper on drug pricing; its formal title is Reforming Biopharmaceutical Pricing at Home and Abroad.
The report states, as a given, that federal policies affect drug pricing, and has a clear perspective on what role those policies should play:
Federal policies that affect drug pricing should satisfy two goals. First, domestic drug prices paid by Americans should be reduced. Second, the price of better health in the future should also be reduced by spurring medical innovation.
We found one of the report’s findings particularly compelling: Pricing in the pharmaceutical drug market suffers from high market concentration and a lack of transparency in the pharmaceutical distribution system.
The report states:
The size of manufacturer rebates and the percentage of the rebate passed on to health plans and patients are secret. The system encourages manufacturers to set artificially high list prices, which are reduced via manufacturers’ rebates but leave uninsured individuals facing high drug prices.
The CEA’s conclusion is that policies to decrease concentration in the supply chain can increase competition and further reduce the price of drugs paid by consumers.
Additionally, the report lays much of the blame for high U.S. drug costs on the fixed-price policies of foreign governments:
Most foreign governments, which are the primary buyers in their respective pharmaceutical markets, force drug manufacturers to comply with pricing rules to gain market access. Through this leverage, foreign governments are able to set drug prices below those that prevail in the United States and erode the returns to innovation manufacturers might otherwise see from selling in their markets.
So, as the CEA report concludes, foreign governments and their citizens are benefiting from the research and development of United States biopharmaceutical companies, but not paying their fair share. That cost is shifted to patients in the United States, who are paying disproportionately high prices for drugs.
The proposed solution: change Medicare and Medicaid programs to help lower domestic prices, and implement reforms within the Food and Drug Administration (FDA) to encourage more robust price competition. Any notion of government price-setting is soundly rejected.
The issuance of the CEA’s white paper is encouraging, as it shows the White House is aware of and sensitive to the serious problem of the high cost of prescription drugs. However, it’s only one very small step toward fixing what is a complex, long-standing problem.
At NextShift, we have created a solution called “RxInstaSave” (RXiS), that squarely addresses the lack of transparency in the pharmaceutical distribution system and provides optimal cost-saving opportunities to consumers. We will be seeking pilot partnerships with manufacturers in the coming months. If you’re interested in learning more, please contact email@example.com.